Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT

Amy I. LynchDepartment of Epidemiology, University of Alabama at Birmingham, RPHB 220E, 1530 3rd Avenue South, Birmingham, AL 55294-0022, USAMarguerite R. IrvinDepartment of Epidemiology, University of Alabama at Birmingham, RPHB 220E, 1530 3rd Avenue South, Birmingham, AL 55294-0022, USABarry R. DavisSchool of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 20186, USACharles E. FordSchool of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 20186, USAJohn H. EckfeldtDepartment of Laboratory Medicine and Pathology, University of Minnesota, Mayo Mail Code 609, 420 Delaware Street SE, Minneapolis, MN 55455, USADonna K. ArnettDepartment of Epidemiology, University of Alabama at Birmingham, RPHB 220E, 1530 3rd Avenue South, Birmingham, AL 55294-0022, USA
2013en
ABI

Annotatsiya

Treatment resistant hypertension (TRH) is defined as uncontrolled hypertension (HTN) despite the use of ≥3 antihypertensive medication classes or controlled HTN while treated with ≥4 antihypertensive medication classes. Risk factors for TRH include increasing age, diminished kidney function, higher body mass index, diabetes, and African American (AA) race. Importantly, previous studies suggest a genetic role in TRH, although the genetics of TRH are largely understudied. With 2203 treatment resistant cases and 2354 treatment responsive controls (36% AA) from the Genetics of Hypertension Associated Treatment Study (GenHAT), we assessed the association of 78 candidate gene polymorphisms with TRH status using logistic regression. After stratifying by race and adjusting for potential confounders, there were 2 genetic variants in the AGT gene (rs699, rs5051) statistically significantly associated with TRH among white participants. The Met allele of rs699 and the G allele of rs5051 were positively associated with TRH: OR = 1.27 (1.12-1.44), P = 0.0001, and OR = 1.36 (1.20-1.53), P < 0.0001, respectively. There was no similar association among AA participants (race interaction P = 0.0004 for rs699 and P = 0.0001 for rs5051). This research contributes to our understanding of the genetic basis of TRH, and further genetic studies of TRH may help reach the goal of better clinical outcomes for hypertensive patients.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba